A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma-Reference-Cited by-同舟云学术

A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma

Published:2017-09-22 Issue:21 Volume:23 Page:6441-6449
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Federico Sara M.,McCarville M. Beth,Shulkin Barry L.,Sondel Paul M.,Hank Jacquelyn A.,Hutson Paul,Meagher Michael,Shafer Aaron,Ng Catherine Y.,Leung Wing,Janssen William E.,Wu Jianrong,Mao Shenghua,Brennan Rachel C.,Santana Victor M.,Pappo Alberto S.,Furman Wayne L.

Funder

National Cancer InstituteCancer CenterCancer Center

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment;Bioactive Materials;2024-12

2. Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed/refractory neuroblastomas post autologous hematopoietic stem cell transplantation;Scientific Reports;2024-09-09

3. Harnessing potential role of gangliosides in immunomodulation and cancer therapeutics;Life Sciences;2024-08

4. In-vitro Expansion and Transduction of Primary Natural Killer Cells Using Feeder Cells Co-expressing Co-stimulatory Receptors and Membrane-bound IL-21;2024-07-25

5. Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma;2024-05-28